{"groups":[{"description":"Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.\n\nChildren with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).","id":"FG000","title":"Antineoplaston Therapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Not evaluable"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Thirty-four patients were recruited between September 1996 and July 2012. All study subjects were seen at the Burzynski Clinic in Houston TX"}